Title of article :
IBD Patients Could Be Silent Carriers for Novel Coronavirus and Less Prone to its Severe Adverse Events: True or False?
Author/Authors :
Baradaran Ghavami ، Shaghayegh Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Gastroenterology and Liver Diseases Research Center - Shahid Beheshti University of Medical Sciences , Shahrokh ، Shabnam Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Gastroenterology and Liver Diseases Research Center - Shahid Beheshti University of Medical Sciences , Hossein-Khannazer ، Nikoo Department of Immunology - School of Medicine, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences , Shpichka ، Anastasia Institute for Regenerative Medicine - Sechenov University , Asadzadeh Aghdaei ، Hamid Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Gastroenterology and Liver Diseases Research Center - Shahid Beheshti University of Medical Sciences , Timashev ، Peter Institute for Regenerative Medicine - Sechenov University , Vosough ، Massoud .Department of Regenerative Medicine - Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology - Academic Center for Education, Culture and Research (ACECR)
Abstract :
Inflammatory bowel diseases (IBDs) are chronic disorders of the gastrointestinal tract. The goal of IBD treatment is to reduce the inflammation period and induce long-term remission. Use of anti-inflammatory drugs including corticosteroids, immunosuppressants and biologicals, is often the first step in the treatment of IBD. Therefore, IBD patients in pandemic of infectious diseases are considered a high-risk group. The public believes that IBD patients are at a higher risk in the current coronavirus 2 pandemic. Nevertheless, these patients may experience mild or moderate complications compared to healthy people. This might be because of particular anti-TNF-α treatment or any immunosuppressant that IBD patients receive. Moreover, these patients might be silent carrier for the virus.
Keywords :
Anti , TNF , α , COVID , 19 , Crohn’s Disease , IBD , Ulcerative Colitis
Journal title :
Cell Journal (Yakhteh)
Journal title :
Cell Journal (Yakhteh)
